{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:17:58Z","timestamp":1769278678131,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00592-016-0904-7","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T04:06:24Z","timestamp":1473739584000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus"],"prefix":"10.1007","volume":"54","clinical-trial-number":[{"clinical-trial-number":"nct00845182","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rodolfo","family":"Guardado-Mendoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto O.","family":"Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia M.","family":"Jim\u00e9nez-Ceja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hansis-Diarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Folli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devjit","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"issue":"3","key":"904_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00125-009-1614-2","volume":"53","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo RA, Banerji MA, Bray GA et al (2010) Determinants of glucose tolerance in impaired glucose tolerance at baseline in the actos now for prevention of diabetes (ACT NOW) study. Diabetologia 53(3):435\u2013445","journal-title":"Diabetologia"},{"issue":"1","key":"904_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","volume":"47","author":"A Gastaldelli","year":"2004","unstructured":"Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47(1):31\u201339","journal-title":"Diabetologia"},{"issue":"6","key":"904_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/diabetes.49.6.975","volume":"49","author":"D Tripathy","year":"2000","unstructured":"Tripathy D, Carlsson M, Almgren P et al (2000) Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the botnia study. Diabetes 49(6):975\u2013980","journal-title":"Diabetes"},{"issue":"5","key":"904_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00125-004-1393-8","volume":"47","author":"D Tripathy","year":"2004","unstructured":"Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L (2004) Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in type 2 diabetes. Diabetologia 47(5):782\u2013793","journal-title":"Diabetologia"},{"issue":"23","key":"904_CR5","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","volume":"84","author":"GJ Cooper","year":"1987","unstructured":"Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84(23):8628\u20138632","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"904_CR6","first-page":"414","volume":"127","author":"P Westermark","year":"1987","unstructured":"Westermark P, Wernstedt C, O\u2019Brien TD, Hayden DW, Johnson KH (1987) Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 127(3):414\u2013417","journal-title":"Am J Pathol"},{"issue":"2","key":"904_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00006676-199508000-00015","volume":"11","author":"H Larsson","year":"1995","unstructured":"Larsson H, Ahren B (1995) Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11(2):201\u2013205","journal-title":"Pancreas"},{"issue":"33","key":"904_CR8","doi-asserted-by":"publisher","first-page":"13992","DOI":"10.1073\/pnas.0906471106","volume":"106","author":"R Guardado-Mendoza","year":"2009","unstructured":"Guardado-Mendoza R, Davalli AM, Chavez AO et al (2009) Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci USA 106(33):13992\u201313997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"904_CR9","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","volume":"178","author":"CA Jurgens","year":"2011","unstructured":"Jurgens CA, Toukatly MN, Fligner CL et al (2011) Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178(6):2632\u20132640","journal-title":"Am J Pathol"},{"issue":"5","key":"904_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00403322","volume":"33","author":"A Clark","year":"1990","unstructured":"Clark A, Saad MF, Nezzer T et al (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33(5):285\u2013289","journal-title":"Diabetologia"},{"issue":"4","key":"904_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF01660981","volume":"421","author":"C Rocken","year":"1992","unstructured":"Rocken C, Linke RP, Saeger W (1992) Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch A Pathol Anat Histopathol 421(4):339\u2013344","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"Suppl 1","key":"904_CR12","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.2337\/diabetes.50.2007.S172","volume":"50","author":"C Sempoux","year":"2001","unstructured":"Sempoux C, Guiot Y, Dubois D, Moulin P, Rahier J (2001) Human type 2 diabetes: morphological evidence for abnormal beta-cell function. Diabetes 50(Suppl 1):S172\u2013S177","journal-title":"Diabetes"},{"issue":"11","key":"904_CR13","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2337\/diabetes.52.11.2759","volume":"52","author":"HL Zhao","year":"2003","unstructured":"Zhao HL, Lai FM, Tong PC et al (2003) Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes. Diabetes 52(11):2759\u20132766","journal-title":"Diabetes"},{"issue":"9","key":"904_CR14","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.2337\/diabetes.52.9.2304","volume":"52","author":"AE Butler","year":"2003","unstructured":"Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52(9):2304\u20132314","journal-title":"Diabetes"},{"issue":"8","key":"904_CR15","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.2337\/db07-0197","volume":"56","author":"CJ Huang","year":"2007","unstructured":"Huang CJ, Lin CY, Haataja L et al (2007) High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56(8):2016\u20132027","journal-title":"Diabetes"},{"issue":"2","key":"904_CR16","first-page":"110","volume":"4","author":"G Kloppel","year":"1985","unstructured":"Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU (1985) Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4(2):110\u2013125","journal-title":"Surv Synth Pathol Res"},{"issue":"4","key":"904_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2337\/db08-1464","volume":"58","author":"AV Matveyenko","year":"2009","unstructured":"Matveyenko AV, Gurlo T, Daval M, Butler AE, Butler PC (2009) Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes 58(4):906\u2013916","journal-title":"Diabetes"},{"key":"904_CR18","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1074\/jbc.271.4.1988","volume":"271","author":"TALM Mirzabeckov","year":"1996","unstructured":"Mirzabeckov TALM, Kagan BL (1996) Pore formation by the cytotoxic islet amyloid polypeptide amylin. J Biol Chem 271:1988\u20131992","journal-title":"J Biol Chem"},{"issue":"1","key":"904_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/db06-0734","volume":"56","author":"RA Ritzel","year":"2007","unstructured":"Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC (2007) Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56(1):65\u201371","journal-title":"Diabetes"},{"issue":"3","key":"904_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1210\/er.2007-0037","volume":"29","author":"L Haataja","year":"2008","unstructured":"Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29(3):303\u2013316","journal-title":"Endocr Rev"},{"issue":"1","key":"904_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0168-8227(92)90074-2","volume":"15","author":"S Enoki","year":"1992","unstructured":"Enoki S, Mitsukawa T, Takemura J et al (1992) Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15(1):97\u2013102","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"904_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2337\/diabetes.47.4.640","volume":"47","author":"SE Kahn","year":"1998","unstructured":"Kahn SE, Verchere CB, Andrikopoulos S et al (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47(4):640\u2013645","journal-title":"Diabetes"},{"issue":"2","key":"904_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00500385","volume":"34","author":"T Sanke","year":"1991","unstructured":"Sanke T, Hanabusa T, Nakano Y et al (1991) Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34(2):129\u2013132","journal-title":"Diabetologia"},{"issue":"2","key":"904_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0168-8227(00)00188-1","volume":"50","author":"CM MacNamara","year":"2000","unstructured":"MacNamara CM, Barrow BA, Manley SE, Levy JC, Clark A, Turner RC (2000) Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance. Diabetes Res Clin Pract 50(2):117\u2013126","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"904_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/diacare.25.2.292","volume":"25","author":"NG Knowles","year":"2002","unstructured":"Knowles NG, Landchild MA, Fujimoto WY, Kahn SE (2002) Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25(2):292\u2013297","journal-title":"Diabetes Care"},{"issue":"8","key":"904_CR26","first-page":"2822","volume":"85","author":"S Makimattila","year":"2000","unstructured":"Makimattila S, Fineman MS, Yki-Jarvinen H (2000) Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab 85(8):2822\u20132827","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"904_CR27","first-page":"608","volume":"19","author":"WC Duckworth","year":"1998","unstructured":"Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19(5):608\u2013624","journal-title":"Endocr Rev"},{"issue":"4","key":"904_CR28","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1172\/JCI111542","volume":"74","author":"WK Ward","year":"1984","unstructured":"Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74(4):1318\u20131328","journal-title":"J Clin Invest"},{"issue":"9","key":"904_CR29","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462\u20131470","journal-title":"Diabetes Care"},{"issue":"3","key":"904_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0014-5793(95)01460-8","volume":"378","author":"MK Badman","year":"1996","unstructured":"Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A (1996) Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378(3):227\u2013231","journal-title":"FEBS Lett"},{"issue":"1","key":"904_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","volume":"52","author":"AE Butler","year":"2003","unstructured":"Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52(1):102\u2013110","journal-title":"Diabetes"},{"issue":"16","key":"904_CR32","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1046\/j.1432-1327.2000.01548.x","volume":"267","author":"CE Higham","year":"2000","unstructured":"Higham CE, Hull RL, Lawrie L et al (2000) Processing of synthetic pro-islet amyloid polypeptide (proIAPP) \u2018amylin\u2019 by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267(16):4998\u20135004","journal-title":"Eur J Biochem"},{"issue":"6","key":"904_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJM200008103430607","volume":"343","author":"JW Hoppener","year":"2000","unstructured":"Hoppener JW, Ahren B, Lips CJ (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343(6):411\u2013419","journal-title":"N Engl J Med"},{"issue":"2","key":"904_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s001250051138","volume":"42","author":"X Hou","year":"1999","unstructured":"Hou X, Ling Z, Quartier E et al (1999) Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia 42(2):188\u2013194","journal-title":"Diabetologia"},{"issue":"8","key":"904_CR35","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.2337\/db05-1566","volume":"55","author":"L Marzban","year":"2006","unstructured":"Marzban L, Rhodes CJ, Steiner DF, Haataja L, Halban PA, Verchere CB (2006) Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. Diabetes 55(8):2192\u20132201","journal-title":"Diabetes"},{"issue":"1","key":"904_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diabetes.53.1.141","volume":"53","author":"L Marzban","year":"2004","unstructured":"Marzban L, Trigo-Gonzalez G, Zhu X et al (2004) Role of beta-cell prohormone convertase (PC)1\/3 in processing of pro-islet amyloid polypeptide. Diabetes 53(1):141\u2013148","journal-title":"Diabetes"},{"issue":"7","key":"904_CR37","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.2337\/diabetes.54.7.2117","volume":"54","author":"JF Paulsson","year":"2005","unstructured":"Paulsson JF, Westermark GT (2005) Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 54(7):2117\u20132125","journal-title":"Diabetes"},{"issue":"3","key":"904_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0014-5793(95)01512-4","volume":"379","author":"P Westermark","year":"1996","unstructured":"Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF (1996) Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379(3):203\u2013206","journal-title":"FEBS Lett"},{"issue":"1","key":"904_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF00404025","volume":"34","author":"E Hartter","year":"1991","unstructured":"Hartter E, Svoboda T, Ludvik B et al (1991) Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34(1):52\u201354","journal-title":"Diabetologia"},{"issue":"5","key":"904_CR40","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/diab.39.5.634","volume":"39","author":"SE Kahn","year":"1990","unstructured":"Kahn SE, D\u2019Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39(5):634\u2013638","journal-title":"Diabetes"},{"issue":"2","key":"904_CR41","doi-asserted-by":"publisher","first-page":"E401","DOI":"10.1152\/ajpendo.00674.2007","volume":"295","author":"MA Abdul-Ghani","year":"2008","unstructured":"Abdul-Ghani MA, Matsuda M, Jani R et al (2008) The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 295(2):E401\u2013E406","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"904_CR42","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.2337\/diab.42.10.1514","volume":"42","author":"A Novials","year":"1993","unstructured":"Novials A, Sarri Y, Casamitjana R, Rivera F, Gomis R (1993) Regulation of islet amyloid polypeptide in human pancreatic islets. Diabetes 42(10):1514\u20131519","journal-title":"Diabetes"},{"issue":"5","key":"904_CR43","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1152\/ajpendo.2001.281.5.E966","volume":"281","author":"A Tura","year":"2001","unstructured":"Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K (2001) Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab 281(5):E966\u2013E974","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5 Pt 1","key":"904_CR44","first-page":"E903","volume":"274","author":"M Clodi","year":"1998","unstructured":"Clodi M, Thomaseth K, Pacini G et al (1998) Distribution and kinetics of amylin in humans. Am J Physiol 274(5 Pt 1):E903\u2013E908","journal-title":"Am J Physiol"},{"issue":"5","key":"904_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11892-011-0211-1","volume":"11","author":"R Bassi","year":"2011","unstructured":"Bassi R, Fiorina P (2011) Impact of islet transplantation on diabetes complications and quality of life. Curr Diabetes Rep 11(5):355\u2013363","journal-title":"Curr Diabetes Rep"},{"issue":"3","key":"904_CR46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2337\/dc07-1831","volume":"31","author":"P Fiorina","year":"2008","unstructured":"Fiorina P, Vergani A, Petrelli A et al (2008) Metabolic and immunological features of the failing islet-transplanted patient. Diabetes Care 31(3):436\u2013438","journal-title":"Diabetes Care"},{"issue":"4","key":"904_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s005920200039","volume":"39","author":"L Polastri","year":"2002","unstructured":"Polastri L, Galbiati F, Bertuzzi F et al (2002) Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 39(4):229\u2013233","journal-title":"Acta Diabetol"},{"issue":"5","key":"904_CR48","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2337\/db12-0242","volume":"62","author":"A Vergani","year":"2013","unstructured":"Vergani A, Fotino C, D\u2019Addio F et al (2013) Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes 62(5):1665\u20131675","journal-title":"Diabetes"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-016-0904-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-016-0904-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-016-0904-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T14:30:00Z","timestamp":1628605800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-016-0904-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s00592-016-0904-7","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]},"assertion":[{"value":"15 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights disclosure"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent disclosure"}}]}}